These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

565 related items for PubMed ID: 12123336

  • 41. A comparison of eflapegrastim to pegfilgrastim in the management of chemotherapy-induced neutropenia in patients with early-stage breast cancer undergoing cytotoxic chemotherapy (RECOVER): A Phase 3 study.
    Cobb PW, Moon YW, Mezei K, Láng I, Bhat G, Chawla S, Hasal SJ, Schwartzberg LS.
    Cancer Med; 2020 Sep; 9(17):6234-6243. PubMed ID: 32687266
    [Abstract] [Full Text] [Related]

  • 42. Pegfilgrastim.
    Curran MP, Goa KL.
    Drugs; 2002 Sep; 62(8):1207-13; discussion 1214-5. PubMed ID: 12010086
    [Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44. Safety and efficacy of pegfilgrastim in children with cancer receiving myelosuppressive chemotherapy.
    André N, Kababri ME, Bertrand P, Rome A, Coze C, Gentet JC, Bernard JL.
    Anticancer Drugs; 2007 Mar; 18(3):277-81. PubMed ID: 17264759
    [Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46. Prevention of chemotherapy-induced neutropenia with pegfilgrastim: pharmacokinetics and patient outcomes.
    Yang BB, Savin MA, Green M.
    Chemotherapy; 2012 Mar; 58(5):387-98. PubMed ID: 23296266
    [Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48. Retrospective comparison of neutropenia in children with Ewing sarcoma treated with chemotherapy and granulocyte colony-stimulating factor (G-CSF) or pegylated G-CSF.
    Milano-Bausset E, Gaudart J, Rome A, Coze C, Gentet JC, Padovani L, Lacarelle B, André N.
    Clin Ther; 2009 Mar; 31 Pt 2():2388-95. PubMed ID: 20110048
    [Abstract] [Full Text] [Related]

  • 49. Pooled analysis of two randomized, double-blind trials comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer.
    Blackwell K, Gascon P, Jones CM, Nixon A, Krendyukov A, Nakov R, Li Y, Harbeck N.
    Ann Oncol; 2017 Sep 01; 28(9):2272-2277. PubMed ID: 28637287
    [Abstract] [Full Text] [Related]

  • 50. Neulasta (pegfilgrastim): a once-per-cycle option for the management of chemotherapy-induced neutropenia.
    Biganzoli L, Untch M, Skacel T, Pico JL.
    Semin Oncol; 2004 Jun 01; 31(3 Suppl 8):27-34. PubMed ID: 15181606
    [Abstract] [Full Text] [Related]

  • 51. Cost-effectiveness of pegfilgrastim versus six days of filgrastim for preventing febrile neutropenia in breast cancer patients.
    Danova M, Chiroli S, Rosti G, Doan QV.
    Tumori; 2009 Jun 01; 95(2):219-26. PubMed ID: 19579869
    [Abstract] [Full Text] [Related]

  • 52. Randomized trial and pharmacokinetic study of pegfilgrastim versus filgrastim after dose-intensive chemotherapy in young adults and children with sarcomas.
    Fox E, Widemann BC, Hawkins DS, Jayaprakash N, Dagher R, Aikin AA, Bernstein D, Long L, Mackall C, Helman L, Steinberg SM, Balis FM.
    Clin Cancer Res; 2009 Dec 01; 15(23):7361-7. PubMed ID: 19920107
    [Abstract] [Full Text] [Related]

  • 53. Eflapegrastim, a Long-Acting Granulocyte-Colony Stimulating Factor for the Management of Chemotherapy-Induced Neutropenia: Results of a Phase III Trial.
    Schwartzberg LS, Bhat G, Peguero J, Agajanian R, Bharadwaj JS, Restrepo A, Hlalah O, Mehmi I, Chawla S, Hasal SJ, Yang Z, Cobb PW.
    Oncologist; 2020 Aug 01; 25(8):e1233-e1241. PubMed ID: 32476162
    [Abstract] [Full Text] [Related]

  • 54. A modified filgrastim regimen does not reduce pain burden compared to pegfilgrastim in women receiving chemotherapy for non-metastatic breast cancer.
    Leung M, Florendo J, Kano J, Marr-Del Monte T, Higgins B, Myers R, Menon T, Jones G.
    Support Care Cancer; 2015 Jun 01; 23(6):1669-77. PubMed ID: 25421443
    [Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57. Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy.
    Kosaka Y, Rai Y, Masuda N, Takano T, Saeki T, Nakamura S, Shimazaki R, Ito Y, Tokuda Y, Tamura K.
    Support Care Cancer; 2015 Apr 01; 23(4):1137-43. PubMed ID: 25576433
    [Abstract] [Full Text] [Related]

  • 58. Efficacy and Safety of Bi-weekly Pegfilgrastim for Dose-dense Chemotherapy-induced Neutropenia in Breast Cancer Patients.
    Mori H, Kubo M, Kai M, Kurata K, Yamada M, Nakamura M.
    Anticancer Res; 2018 Jul 01; 38(7):4381-4386. PubMed ID: 29970577
    [Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60. Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States.
    Lyman G, Lalla A, Barron R, Dubois RW.
    Curr Med Res Opin; 2009 Feb 01; 25(2):401-11. PubMed ID: 19192985
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 29.